
ESOCAP HOLDS A SCIENTIFIC ADVISORY BOARD MEETING IN EOSINOPHILIC ESOPHAGITIS

Basel, Switzerland, June 14th, 2018

EsoCap AG organized a scientific advisory board meeting with eight international experts in Eosinophilic Esophagitis (EoE) in Zürich on June 14th, 2018.

Prof. Dr. Werner Weitschies, Head of the Center of Drug Absorption and Transport at the University of Greifswald gave a keynote presentation on EsoCap's unique drug delivery platform, which allows the specific, site-directed treatment of diseases of the upper gastrointestinal tract.

The experts discussed the role of EsoCap's technology for the topical treatment of EoE and later explored the broader application of EsoCap's drug delivery platform in further diseases of the esophagus with established and novel drug substances.

The participants in this scientific advisory board meeting included eight distinguished gastroenterologists from the EU, Switzerland and the USA, all internationally recognized for their expertise in EoE.

"I am highly impressed by the technology" said Prof. Dr. Arjan Bredenoord, President of EUREOS (EUROpean society of Eosinophilic Oesophagitis). "We are excited about the impact on future treatment options for diseases of the esophagus."

"The insightful discussion with the experts will allow EsoCap to rapidly move into clinical

testing of our smart drug delivery platform" said Isabelle Racamier, CEO of EsoCap AG. "Our technology may be beneficial in at least 6 indications affecting a total of 370 Mio patients."

About EsoCap

EsoCap AG is a privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through the development of a unique topical drug delivery platform.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short transit times with less than two seconds from the mouth to the stomach.

EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocapbiotech.com.





EsoCap

Contact:

Isabelle Racamier, CEO

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com